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Abstract
Coagulation upon blood-contacting biomaterials remains a problem for short and long-term
clinical applications. This study examined the ability of copper(II)-doped silicone surfaces to
generate nitric oxide (NO) and locally inhibit coagulation. Silicone was doped with 3-micron
copper (Cu(0)) particles yielding 3 to 10 weight percent (wt%) Cu in 70-μm thick Cu/Silicone
polymeric matrix composites (Cu/Si PMCs). At 3, 5, 8 and 10 wt% Cu doping, the surface
expression of Cu was 12.1 ± 2.8%, 19.7 ± 5.4%, 29.0 ± 3.8%, and 33.8 ± 6.5% respectively. After
oxidizing Cu(0) to Cu(II) by spontaneous corrosion, NO flux, JNO (mol*cm−2*min−1), as
measured by chemiluminescence, increased with surface Cu expression according to the
relationship JNO =(1.63 %SACu −0.81) ×10−11, R2 = 0.98 where %SACu is the percentage of
surface occupied by Cu. NO flux at 10 wt% Cu was 5.35± 0.74 ×10−10 mol*cm−2*min−1. The
clotting time of sheep blood exposed to these surfaces was 80 ± 13s with pure silicone and 339 ±
44s when 10 wt% Cu(II) was added. SEMs of coatings showed clots occurred away from exposed
Cu-dendrites. In conclusion, Cu/Si PMCs inhibit coagulation in a dose-dependent fashion related
to the extent of copper exposure on the coated surface.
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Introduction
Over 200 million blood-contacting biomaterials are presently used in clinical applications
such as catheters, vascular grafts, heart valves, extracorporeal membrane oxygenation
(ECMO), cardiopulmonary bypass circuits, artificial kidneys, ventricular assist devices,
glucose sensors, and stents [1]. In all these applications, it is important to reduce surface-
induced blood activation in order to increase the useful life of the device and reduce
thromboembolic complications. Thrombosis is especially problematic in long-term clinical
applications such as artificial lungs (arteriovenous CO2 removal, ECMO, thoracic artificial
lungs) where the need for efficient gas transfer requires a larger surface area [2]. Currently,
the administration of conventional systemic anticoagulants such as heparin, low-molecular-
weight heparin, warfarin, aspirin, and clopidogrel is standard clinical practice to inhibit
blood coagulation. Usage of newer GPIIb/IIIa blockers like reopro, aggrastat and integrilin
to achieve the same goal are also on the rise [3]. Unfortunately, these anticoagulants act
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systemically and have long half-lives. Thus, they limit coagulation at the artificial surface, at
surgical sites, and within native blood vessels. The result is longer device lifespan but also
increased risk of bleeding complications [3 – 5].
A relatively new approach to reduce clot formation on biomaterials is through surface
release or generation of NO [6,7]. NO is a free radical gas produced by the endothelium to
maintain hemostasis [8 –11]. The gas reduces platelet activation by inhibiting agonist
binding to their surface receptors. It freely diffuses into platelets to initiate the NO/cGMP
[10,11] pathway that in turn phosphorylates G protein-coupled surface receptors, changing
their conformation to decrease binding affinities of agonists. Commonly known G protein-
coupled receptors on the platelet include thrombin, thromboxane A2, and adenosine
diphosphate receptors. The gas also reduces secondary activation of circulating platelets by
inhibiting the release of platelets’ intracellular granules. This is achieved by blocking the
release of their calcium stores needed for actin-myosin interaction that is required for
platelets to change their shape and release their granules.
Unlike other platelet inhibitors, NO has a very short half-life (milliseconds), as it is quickly
taken up by RBCs, platelets, and other NO scavengers. Thus, the anticoagulant effect occurs
near the surface that releases or generates NO and has no effect on coagulation downstream.
NO generation from polymeric materials impregnated with Cu and other transition metal
particles has been described [6,7]. In brief, these metallic particles catalyze the release of
NO from NO-donors in blood. In the case of Cu, the metal exists mostly as Cu(II) on the
surface of the polymer after oxidation. Reducing agents convert Cu(II) to Cu(I), which then
interacts with NO-donors (Figure 1a) to produce thiolate ions, Cu(II), and NO gas. The
thiolate ions then combine to form disulfides by reducing Cu(II) back to Cu(I). The entire
reaction repeats to continuously generate NO. Once NO is generated, numerous reactions
affect its concentration in blood (Figure 1b). In addition to binding and inhibiting platelets,
NO can form nitrites by oxidative species, including ceruloplasmin,[12,13] and bind to
hemoglobin and form methemoglobin. Plasma deoxyhemoglobin can also reduce NO2−
back to NO. Plasma deoxyhemoglobin is normally associated with blood trauma caused by
extracorporeal circulation during CPB or ECMO.
These modified polymers could be used to coat blood contacting surfaces or the blood-
contacting device could be constructed wholly out of NO-generating materials. For example,
the artificial lung’s gas exchange membrane could be made wholly from silicone that is
doped with Cu. To this end, the following study characterizes the relationship between the
surface exposure of Cu surface NO flux, and the resultant anticoagulant effect from a
silicone-Cu polymeric matrix composite (Cu/Si PMC). The aim is to provide a guide to their
future use in any device with significant blood-biomaterial interactions.
Materials and Methods
In Vitro Test System
An in vitro test system was created by coating standard Hemochron tubes (P214 flip-top,
ITC, Edison, NJ) with PMC at various weight percents of Cu. The tubes were emptied of
their kaolin activator, rinsed with deionized water, and dried before coating. Three micron
particles of elemental Cu (Sigma Aldrich Chemical Co. St. Louis, MO) were blended into
part A of a two-part R21-2615 silicone resin (Nusil Silicone Technology, CA). An equal
volume of silicone resin Part B was added followed by one mL of acetone per two mL of
blend. The mixture was then stirred and sonicated (Branson 5510 Sonicator Bath, Norwich
NY) for 60 minutes to create a uniform suspension. Cu microparticles were then added to
create 0, 3, 5, 8, and 10 weight percent (wt%) Cu/Si PMCs. The hemochron tubes were
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loaded with 0.3 mL of the mixture and rolled over a flat surface to eliminate uncoated
patches. The tubes were then loaded horizontally into a rotisserie (Figure 2) and cured by
rotating the tubes in the x-y plane at 1.5 rev min−1 for 24 hours at ambient temperature.
The resulting, cured coatings had thicknesses of 70 μm approximately. These coatings were
oxidized at 37°C for 24 hours by bathing them in PBS at pH 7.4 using the Innova 4000
incubator-shaker. Bathing in PBS oxidizes Cu to Cu(II) by spontaneous corrosion of
metallic copper [6], thus creating a Cu(II)/Si PMC. The hemochron tubes were then rinsed
for approximately 2 minutes with deionized water and dried for testing.
PMC Surface Analysis
The presence of Cu on the Cu/Si PMC was verified with energy dispersive x-ray
spectroscopy (EDAX Inc. Mahwah NJ). The Cu/Si PMC layer was coated on to tubes as
described above, but peeled and sectioned into two cm2 pieces prior to oxidation and further
testing. Twelve surface locations per wt% were then analyzed with EDS. The following
settings were used: input count rate = 1000cps, energy resolution = 135eV, peak/background
= 100, and the scanned surface area = 4 mm2. SEMs of surfaces analyzed with EDS were
then imported into Image J (NIH, Bethesda, MD) for quantifying the percentage of Cu
exposed on the surface. The images were converted into a two-dimensional black and white
binary map and then processed using the particle analysis package to quantify the percentage
of total surface area occupied by Cu.
Measurement of NO Flux and Clotting Times
NO generation from 0, 3, 5, 8, and 10 wt% PMC-coated tubes (N = 6 each) was measured
by gas-phase chemiluminescence. Specifically, 2.75 ± 0.5 cm2 coated pieces of the
hemochron tube wall were introduced into a 1 μM S-nitrosoglutathione (GSNO) to activate
a chemiluminescence reaction in a standard setup as shown in Figure 3. The NO generation
profiles are decaying, left-skewed Gaussian curves (see Figure 4). A peak NO flux is
reached initially; thereafter the GSNO concentration decreases and NO flux decreases. NO
generation was measured for at least 30 minutes from each sample, and the peak flux was
recorded for presentation.
Clotting times of sheep blood were measured for the 0, 3, 5, 8, and 10 wt% Cu-doped PMC-
coated tubes (N = 6 each) using the coated hemochron tubes. Non-heparinized sheep blood
(0.4ml) was dispensed into the tubes immediately after being drawn. Unlike typical
activated clotting time assays, the tubes did not contain any procoagulant activator. Thus,
the artificial surface was the only activator present. All other methods, including detection of
a formed clot, followed standard Hemochron activated clotting time protocols. Thus,
clotting time was measured as the time elapsed between loading the Hemochron tube with
blood and when the Hemochron detected solid clot. All in vitro clotting time experiments
were performed in atmospheric level of PO2, or approximately PO2 = 150 mmHg
Clot Distribution on NO generating Cu(II)/Si PMCs
To examine the mechanism of anticoagulation, Hemochron tubes were coated with 0 or 10
wt% Cu-doped silicone and filled with approximately 5 ml of blood. The tubes were placed
on an Eberbach model EL687 shaker (Eberbach Labtools, Ann Arbor, MI) at 50 cycles/min
within a 37° C incubator for 30, 60, 90, 240, 360, and 480 seconds. After incubation, the
surfaces were gently rinsed with saline solution until the effluent was clear and fixed with
2% gluteraldehyde (Sigma Aldrich Chemical Co. ST. Louis, MO). The samples were
imaged with a Philips XL30 FEG SEM to examine protein adsorption and platelet adhesion
to the surface.
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One-way ANOVA with Tukey’s post hoc tests was performed to compare the NO flux,
clotting times and surface area of Cu using the weight percent of copper as the independent
variable. A p-value < 0.05 is regarded as significant. All data is expressed as mean ±
standard deviation.
Results
PMC’s Surface Microstructure and Composition
In Figure 5, the surfaces of control and Cu(II)/Si coatings show different surface
morphologies. As expected particle aggregates are not present on control surfaces, whereas
dendrites of Cu microparticles are present on the non-control surfaces. The presence of Cu
dendrites, as verified by EDS microanalysis, is shown in Figure 6. SEMs of the Cu/Si PMC
showing Cu dendrites were first analyzed with energy dispersive spectroscopy. The result
showed a mapping of Cu in Figures 6B and 6C similar to the Cu dendrite pattern of the SEM
in Figure 4A. The energy spectra in Figure 6D also shows the corresponding Cu peaks.
The percentage of the surface area of membranes occupied by Cu was quantified with image
J to be 12.1 ± 2.8%, 19.7 ± 5.4%, 29.0 ± 3.8% and 33.8 ± 6.5% at 3, 5, 8 and 10 wt% Cu
doping respectively (see Figure 7). These results are significantly different from 0 wt%
group and from each other (p < 0.05). The only exception is that the percentage of Cu/Si
surface area occupied by Cu on the 10 wt% Cu surface was not significantly difference from
that of the 8 wt% Cu group.
Relationships Between Surface Expression of Cu, NO Flux, and Clotting Times of PMCs
The peak NO flux increased with surface expression of Cu from 2.13 × 10−10 ± 0.38× 10−10
mol cm−2 min−1 at 12.1 ± 2.8% expression to 5.35 ×10−10 ± 0.73× 10−10 mol cm−2 min−1
at 33.8 ± 6.5% expression (Figure 8). The average peak flux of each group is significantly
different from the control (p < 0.05) and from each other (p < 0.05). The one exception is
that flux from the 33.8 ± 6.5% surface expression group was not significantly different from
that of the 28.9 ± 3.7 % surface expression group (p = 0.4). These fluxes were all greater
than published human endothelial NO flux in the range of (0.5–4) ×10−10mol cm−2 min−1
[12]. A linear fit of the relationship between NO flux and surface expression of Cu yielded
JNO = (0.16(%SACU) − 0.34) × 10−10, R2 = 0.99.
Accordingly, clotting times also increased with Cu surface expression from 80 ± 13 seconds
at 0% Cu surface expression to 339 ± 44.5 seconds at 33.8 ± 6.5% Cu surface expression
(see Figure 8). The average clotting time of each group is significantly different from control
and from each other (p < 0.05). However the clotting time of the 33.8 ± 6.5% Cu surface
expression group was not significantly different from that of the 28.9 ± 3.7% Cu surface
expression group (p = 0.29). A linear fit of the relationship between clotting time in seconds
(CT) and surface expression yielded CT = 8.08(%SACU) + 55.71, R2 = 0.94.
Clots on Coated Surfaces
Scanning electron micrographs of clots on control and NO-releasing surfaces are shown in
Figure 9. Following exposure to blood for different durations, an adsorbed protein layer was
present at all times, indicating that NO had no significant effect on total protein adsorption.
However, Cu-doped surfaces had a smaller number of adhered platelets. In particular, it can
be seen that areas around exposed Cu dendrites are free from platelets. Thus, the effect of
NO on coagulation appears to be primarily keeping platelets from adhering to the adsorbed
protein layer and perhaps keeping platelets that adhere from activating.
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Overall, these results indicate that Cu catalyzes NO formation effectively in these Cu/Si
composites, and the NO formation leads to significant inhibition of clotting. Clotting times
were 1.33 and 4.24 times longer at 3 and 10 wt%, respectively, than without Cu.
Furthermore, the NO flux and resultant increase in clotting time is dependent primarily on
the amount of copper exposed on the surface of silicone. At higher Cu weight percents,
however, there are diminishing returns to adding more copper. The surface concentration of
copper does not increase significantly between 8 and 10 wt% (Figure 7), as increasing
amounts of Cu get trapped inside the bulk material. Thus, there is little improvement in NO
flux and clotting time at higher Cu concentrations.
Thus, at greater than 8%, a significant amount of copper is buried within the bulk material
and not assisting in NO generation. If greater NO generation were desired, surface
processing would be necessary. A base layer of pure silicone could be laid down first,
followed by a second, far thinner layer with a high Cu concentration. The thin layer would
keep Cu from being subsumed within the bulk material. In the case of artificial lung
membranes, this technique would reduce overall copper content and might better maintain
the gas permeability of the membrane.
These results also indicate that each wt% surface was capable of NO fluxes on the same
order as endothelial cells [14]. However, in vivo NO flux will depend on the concentration
of a variety of NO-donors in present in blood and the reaction rate between each donor and
Cu(I). In blood, the total concentration of GSNO and other low molecular weight NO donors
such as S-Nitrosocysteine (CysNO), S-nitrosohomocysteine (HCysNO), and S-
nitrosocysteinylglycine (CysGlyNO) in healthy subjects ranges across several orders of
magnitude, from nanomolar to micromolar concentrations [15, 16]. Thus, predicting NO
fluxes in blood are difficult.
In this study, 1μM of GSNO was used as the substrate for in vitro studies. The concentration
of GSNO in blood is about one-third of that used here, 320 ± 60 nM, but this is augmented
by the presence of low molecular weight NO donors. In addition, the rate of reaction
between Cu(I) and these donors is faster than between Cu(I) and GSNO [17]. Thus, NO
generation and the rate of clot formation may be different in vivo and vary across test
subjects.
Generation of NO will also vary with time. If not supplemented, concentrations of NO
donors will decrease as these molecules are cleaved to generate NO. In situations in which
small surface area devices such as stents and arterial and venous lines are used, consumption
would be minimal. In large surface area devices such as artificial lungs, consumption would
be rapid, as there will be more catalytic sites for NO generation and widely studied synthetic
RSNOs supplements such as S-Nitrosoglutathione and S-Nitroso-N-acetylpenicillamine
(SNAP) would likely have to be infused into the device inlet to maximize the local NO
generation. SNAP will be better suited for infusion, as it has been shown to be more stable
than other S-nitrosothiols that lead to inconsistency due to their highly unstable nature [18,
19].
Ultimately, choosing an appropriate level of copper for a biomaterial depends greatly on the
application. First, the minimum amount of Cu should be used to avoid any potential risk of
high blood Cu concentrations. The amount of leached copper was not measured here
because of the short blood exposure times. In this study, at 10 wt%, 60 mg of copper was
used per coating over a surface area of 33 cm2. If a similar coating were applied to a stent
(surface area = 6 cm2) and adult sized oxygenators (surface area up to 25,000 cm2), the total
amount of Cu that could potentially leach would be 10 mg and 45,000 mg respectively.
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Thus, even if all of the Cu leached from stents, the amount would be negligible compared to
the recommended daily intake. The amount that could leach from adult size oxygenators is
higher than the tolerable daily intake, but this amount would leach slowly over the device’s
lifespan. Moreover, it is likely that only surface exposed copper would leach in significant
amounts. The rate Cu leaching into plasma has been studied in a 4 h, rabbit model of
extracorporeal life support [20]. There, a 10 wt% Cu circuit with a surface area of 0.02 m2
was used in 2–3 kg rabbits The long term Cu leaching of these surfaces was also addressed
by measuring the Cu content over seven days in a similar, saline filled extracorporeal circuit.
There was a two-fold increase in plasma Cu to 5.9 ± 0.2 μg/dl after 4h. After 7 days, Cu
levels in saline was 23.4 ± 8 μg/dl. This indicates a very slow rate of copper corrosion to
copper ions within the coatings containing copper nanoparticles.
Additionally, the level of Cu that should be used will depend on the application and its
duration. Large bore cannulae with relatively small surface area to volume ratios and high
blood flow velocities will require lesser amounts of NO release, whereas artificial lung
surfaces, with high surface area to volume ratios and low blood flow velocities will require
far more NO release. Moreover, the longer the application, the greater anticoagulation
required. This study indicates that weight percents between 5% and 8% would be the most
likely therapeutic range if the copper were in the bulk polymer.
Despite these positive results, this study is limited by the short periods of blood biomaterial
contact and the relatively static setting. Future long-term in vivo studies are needed to
determine the effectiveness of the Cu/Si PMC on coagulation for periods of hours to days
under blood flow. The hemochron tube wall velocity is 0.08 m/min, whereas the average
blood flow velocity is anywhere from 0.4 m/min in an artificial lung [21] to 35 m/min in an
ECMO cannula [22]. The static setting of this study results in pooling of reactants, including
activated procoagulant molecules and possibly Cu leaching from the surface into the bulk
fluid. In a dynamic system, both would be washed into circulation, reducing their effect at
the biomaterial surface.
Conclusion
Results from this study indicate that Cu catalyzes NO formation effectively in silicone-Cu
composites, and the NO formation leads to significant inhibition of clotting. Both NO flux
and clotting time increase linearly with surface copper exposure. Copper exposure increases
with the weight percent of copper in the PMC, but reaches a point of diminishing returns
above 8 wt%. At 8 and 10 wt%, 29 and 34% of the surface is copper, respectively, and the
clotting time is 3.61 and 4.24 times greater than with pure silicone, respectively. Future
long-term in vivo studies are still needed to determine the effectiveness of this surface on
coagulation for periods of hours to days under blood flow.
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Cu-mediated NO generation model (6). The in vitro NO generation from these surfaces can
be measured accurately however the amount of NO generated in vivo from these surface still
remains in question. Ceruloplasmin, a multicopper oxidase synthesized and secreted by the
liver into plasma catalyzes the oxidation of NO into NO2 concomitantly with cupric (Cu2+)
to cuprous (Cu+) reduction (13, 14). Perhaps, with other NO scavengers in plasma, only a
fraction of the NO generated diffuses into platelets to activate the NO/cGMP pathway to
inhibit platelet activation.
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Curing of coated hemochron tubes at ambient temperature and 1.5 rev min−1. All tubes ware
capped with their flip tops during curing.
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Chemiluminescence reaction and reaction setup
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Representative NO generation profiles for 0 (Control), 3, 5, 8, and 10 wt% Cu PMC coated
surface.
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Surface of silicone coated control (A), and surfaces of Cu(II)/Si PMC coatings at 3 wt% Cu
(B), 5 wt% Cu (C), and 10 wt% Cu (D). The treated surfaces all show exposed Cu dendrites
necessary for nitric oxide generation.
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Energy dispersive X-ray microanalysis results confirming the presence of Cu on Cu/SI PMC
coated surfaces: SEM of Cu/Si PMC showing Cu dendrites (A) were analyzed with energy
dispersive spectroscopy. The result showed a mapping of Cu in the L (B), and K (C) shells
similar to the Cu dendrite pattern of the SEM. The energy spectra in D) shows the
corresponding Cu peaks.
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The percentage of silicone surface-Cu as function of wt% Cu increased from 12.1% at 3wt%
Cu to 33.82% at 10wt%Cu. The percentage of surface Cu in each wt% Cu coating group
was significantly different from control and all the other groups (p < 0.05) with one
exception. The 10 wt% Cu group was not significantly different from the 8 wt% Cu (p=0.1).
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Average clotting time and NO flux from PMC coated surfaces for 0 (Control), 3, 5, 8, and
10 wt% Cu polymeric matrix composites. The average clotting time and average peak NO
flux of each group is significantly different from control and from each other (p < 0.05).
However the clotting time and peak flux of the 10wt% Cu group was not significantly
different from that of the 8wt% Cu group (p = 0.29 and p = 0.4 respectively).
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SEMs demonstrating platelet adherence to control (0 wt% Cu) and 10 wt% Cu materials
after 30 and 480 seconds.
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